Paratek completes $330M acquisition of OptiNose; OptiNose stockholders receive $9/share cash plus CVRs

OptiNose, Inc.

All outstanding OptiNose shares converted into $9 cash and one CVR per share (up to $5 additional).
CVRs pay $1/share if XHANCE net sales ≥$150M in any calendar year by Dec 31, 2028; $4/share if ≥$225M by Dec 31, 2029.
OptiNose common stock to be delisted from Nasdaq; trading halted pre-open on May 21, 2025.
Evan Loh becomes sole director and CEO of surviving OptiNose subsidiary; prior board and officers resigned.
Transaction financed by Paratek, B-FLEXION, Novo Holdings, and Oaktree debt financing.

item 1.02item 2.01item 3.01item 3.03item 5.01item 5.03item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.